- The P-III JADE MONO-2 study involves assessing of Abrocitinib (qd, 100mg & 200mg) vs PBO in 391 patients with mod. to sev. AD aged ≥12yrs. for 12wks.
- The P-III JADE MONO-2 study results: met its 1EPs & 2EPs i.e, improvement in IGA score of clear (0) or almost clear (1) skin, ≥75% change in baseline in EASI score & 4point or larger reduction in itching measured with a decrease in magnitude in PSAAD respectively, safety results are consistent with JADE MONO-1 study
- Abrocitinib is an oral JAK-inhibitor, modulating multiple cytokines involved in the pathophysiology of AD, including IL-4, IL-13, IL-31, and interferon-gamma and has received FDA’s BT designation in Feb’2018
Click here to read full press release/ article | Ref: Pfizer | Image: Pharmaceutical Technology